BOND PRIME
LIVE

Serial Number

79378815

Owner

Leica Biosystems Melbourne Pty Ltd

Attorney

ALEXIS P. GRILLI

Filing Date

Aug 17, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BOND PRIME Trademark

Serial Number: 79378815 • Registration: 8268333

BOND PRIME is a trademark filed by Leica Biosystems Melbourne Pty Ltd on August 17, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Leica Biosystems Melbourne Pty Ltd

495 Blackburn Rd

Entity Type: 82

Trademark Details

Filing Date

August 17, 2023

Registration Date

May 26, 2026

Published for Opposition

April 7, 2026

Goods & Services

Diagnostic apparatus and instruments for medical use for staining and/or visualization of tissue or cell based samples for diagnostic or medical use for pathology purposes, pathological assessment, pathological testing, or performing immunohistochemistry and in situ-hybridisation staining reactions, and histological and pathological staining; diagnostic apparatus for detection of tissue and/or cell based samples, all for medical purposes for pathology purposes, pathological assessment, pathological testing, or performing immunohistochemistry and in situ-hybridisation staining reactions, and histological and pathological staining; medical analysis and medical measuring apparatus, namely medical diagnostic instruments for the analysis of body fluids and tissue for medical diagnostic uses; medical apparatus and instruments for pathology purposes, namely, for pathological assessment, pathological testing, or performing immunohistochemistry and in situ-hybridisation staining reactions, and histological and pathological staining; apparatus for use in medical analysis, namely, medical diagnostic apparatus for pathology purposes, pathological assessment, pathological testing, or performing immunohistochemistry and in situ-hybridisation staining reactions, and histological and pathological staining; testing apparatus for medical purposes, namely, histopathology instruments, haematology instruments, both for clinical purposes, for pathology purposes, pathological assessment, pathological testing, or performing immunohistochemistry and in situ-hybridisation staining reactions, and histological and pathological staining; diagnostic medical apparatus namely, histopathology instruments, haematology instruments, both for clinical purposes, for pathology purposes, pathological assessment, pathological testing, or performing immunohistochemistry and in situ-hybridisation staining reactions, and histological and pathological staining, for promoting and controlling reaction on microarrays or under slide covertiles; in-vitro diagnostic testing apparatus incorporating chemical reagents for medical use; medical specimen collection slides for specimen collection in surgery

diagnostic apparatus and instruments, not for medical purposes, for staining and visualisation of tissue or cell based samples for research and scientific use; laboratory apparatus for detection of tissue and/or cell based samples not for medical purposes; recorded and downloadable software for identifying and diagnosing cancer and other diseases and processing digital images; analysis apparatus for laboratory use for analyzing the results of tissues and cell based samples obtained through operation of tissue and cell sample staining apparatus not for medical purposes; diagnostic measuring apparatus used to identify and/or diagnose cancer and other diseases, not for medical use; diagnostic laboratory testing apparatus incorporating chemical reagents for analysing the results of tissues and cell based samples, not for medical use

Medical research; installation and integration of software, including within existing hospital and laboratory infrastructure; maintenance, servicing, updating and upgrading of software; all the aforementioned for use in connection with medical analysis, diagnosis and research

pharmaceutical and veterinary preparations namely reagents for medical and diagnostic purposes reagents for veterinary purposes; diagnostic preparation for medical use; antibody reagents used for the detection of antigens in cells and tissue for medical purposes; chemical reagents and diagnostic preparations for medical and veterinary purposes; medical diagnostic reagents; clinical medical reagents; medical diagnostic reagents for immuno-histochemistry detection and in situ-hybridisation detection; diagnostic preparations in the nature of in situ-hybridisation probes for medical and veterinary purposes; diagnostic preparations in the nature of epitope retrieval solutions; enzymes and enzyme preparations for medical and diagnostic purposes; diagnostic preparations in the nature of diagnostic histological dye and stain solutions for medical purposes; dewaxing and wash buffers used with the aforementioned preparations for use in disease testing; diagnostic preparations for clinical or medical laboratory use

Filing History

LIMITATION OF GOODS RECEIVED FROM IB
May 28, 2026 LIMG
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 26, 2026 NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 26, 2026 NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 26, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
May 26, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 7, 2026 NPUB
PUBLISHED FOR OPPOSITION
Apr 7, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 1, 2026 NONP
EXPARTE APPEAL TERMINATED
Mar 16, 2026 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 16, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 16, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 16, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 16, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 16, 2026 CNEA
EX PARTE APPEAL-INSTITUTED
Mar 4, 2026 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Mar 4, 2026 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Mar 4, 2026 EXAF
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 3, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 3, 2026 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 3, 2026 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 5, 2025 GNFN
FINAL REFUSAL E-MAILED
Sep 5, 2025 GNFR
FINAL REFUSAL WRITTEN
Sep 5, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 4, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 4, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 4, 2025 TROA
REFUSAL PROCESSED BY IB
Mar 22, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 4, 2025 RFCS
REFUSAL PROCESSED BY MPU
Mar 4, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 1, 2025 RFCR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 1, 2025 OPNX
NON-FINAL ACTION WRITTEN
Feb 28, 2025 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Feb 26, 2025 RFWR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 12, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 12, 2025 OPNR
NON-FINAL ACTION WRITTEN
Apr 29, 2024 CNRT
ASSIGNED TO EXAMINER
Apr 17, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 19, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 15, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 14, 2023 REPR